Literature DB >> 32635531

Integrated Genomic Analysis of Chromosomal Alterations and Mutations in B-Cell Acute Lymphoblastic Leukemia Reveals Distinct Genetic Profiles at Relapse.

Maribel Forero-Castro1, Adrián Montaño2, Cristina Robledo2, Alfonso García de Coca3, José Luis Fuster4, Natalia de Las Heras5, José Antonio Queizán6, María Hernández-Sánchez2, Luis A Corchete-Sánchez2,7, Marta Martín-Izquierdo2, Jordi Ribera8, José-María Ribera9, Rocío Benito2, Jesús M Hernández-Rivas2,7,10.   

Abstract

The clonal basis of relapse in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is complex and not fully understood. Next-generation sequencing (NGS), array comparative genomic hybridization (aCGH), and multiplex ligation-dependent probe amplification (MLPA) were carried out in matched diagnosis-relapse samples from 13 BCP-ALL patients to identify patterns of genetic evolution that could account for the phenotypic changes associated with disease relapse. The integrative genomic analysis of aCGH, MLPA and NGS revealed that 100% of the BCP-ALL patients showed at least one genetic alteration at diagnosis and relapse. In addition, there was a significant increase in the frequency of chromosomal lesions at the time of relapse (p = 0.019). MLPA and aCGH techniques showed that IKZF1 was the most frequently deleted gene. TP53 was the most frequently mutated gene at relapse. Two TP53 mutations were detected only at relapse, whereas the three others showed an increase in their mutational burden at relapse. Clonal evolution patterns were heterogeneous, involving the acquisition, loss and maintenance of lesions at relapse. Therefore, this study provides additional evidence that BCP-ALL is a genetically dynamic disease with distinct genetic profiles at diagnosis and relapse. Integrative NGS, aCGH and MLPA analysis enables better molecular characterization of the genetic profile in BCP-ALL patients during the evolution from diagnosis to relapse.

Entities:  

Keywords:  IKZF1; TP53; acute lymphoblastic leukemia (ALL); array comparative genomic hybridization (aCGH); multiplex ligation-dependent probe amplification (MLPA); next-generation sequencing (NGS); relapse

Year:  2020        PMID: 32635531     DOI: 10.3390/diagnostics10070455

Source DB:  PubMed          Journal:  Diagnostics (Basel)        ISSN: 2075-4418


  4 in total

1.  Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.

Authors:  Franco Locatelli; Gerhard Zugmaier; Carmelo Rizzari; Joan D Morris; Bernd Gruhn; Thomas Klingebiel; Rosanna Parasole; Christin Linderkamp; Christian Flotho; Arnaud Petit; Concetta Micalizzi; Noemi Mergen; Abeera Mohammad; William N Kormany; Cornelia Eckert; Anja Möricke; Mary Sartor; Ondrej Hrusak; Christina Peters; Vaskar Saha; Luciana Vinti; Arend von Stackelberg
Journal:  JAMA       Date:  2021-03-02       Impact factor: 56.272

2.  Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis.

Authors:  Franco Locatelli; Gerhard Zugmaier; Noemi Mergen; Peter Bader; Sima Jeha; Paul-Gerhardt Schlegel; Jean-Pierre Bourquin; Rupert Handgretinger; Benoit Brethon; Claudia Rössig; William N Kormany; Puneeth Viswagnachar; Christiane Chen-Santel
Journal:  Blood Adv       Date:  2022-02-08

3.  The long-term outcome and risk factors for precursor B cell acute lymphoblastic leukemia without specific fusion genes in Chinese children: experiences from multiple centers.

Authors:  Pinli Zou; Min Zhou; Jinquan Wen; Xin Liao; Yali Shen; Haiyan Liu; Lin Song; Jianwen Xiao
Journal:  Bosn J Basic Med Sci       Date:  2022-04-01       Impact factor: 3.363

4.  Loss of Heterozygosity in the Tumor DNA of De Novo Diagnosed Patients Is Associated with Poor Outcome for B-ALL but Not for T-ALL.

Authors:  Natalya Risinskaya; Yana Kozhevnikova; Olga Gavrilina; Julia Chabaeva; Ekaterina Kotova; Anna Yushkova; Galina Isinova; Ksenija Zarubina; Tatiana Obukhova; Sergey Kulikov; Hunan Julhakyan; Andrey Sudarikov; Elena Parovichnikova
Journal:  Genes (Basel)       Date:  2022-02-23       Impact factor: 4.096

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.